Search Results

• • 283 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3

  Authors:Wei Wang, Yan Zhang, Ming Lv, Jiannan Feng, Hui Peng, Jing Geng, et al.From:Journal of Ovarian Research (Vol. 7, Issue 1) Peer-Reviewed

  Nov. 26, 20148,451 words Article 1510LAuthor(s): Wei Wang1,2 , Yan Zhang3 , Ming Lv2 , Jiannan Feng1,2 , Hui Peng4 , Jing Geng2 , Zhou Lin2 , Tingting Zhou2 , Xinying Li2 , Beifen Shen2 , Yuanfang Ma1 and Chunxia Qiao2 Introduction An antibody (Ab),...

• Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment

  Authors:Sung Hyun Yoon, Young Hoon Kim, Yoon Jin Lee, Jihoon Park, Jin Won Kim, Hye Seung Lee, et al.From:PLoS ONE (Vol. 11, Issue 8) Peer-Reviewed

  Aug. 12, 20164,030 words Report 1530LBackground Image texture analysis is a noninvasive technique for quantifying intratumoral heterogeneity, with derived texture features reported to be closely related to the treatment outcome of tumors. Gastric cancer...

• Pertuzumab (Genentech, a member of the Roche Group) in combination with Herceptin (trastuzumab) and docetaxel chemotherapy

  From:Formulary (Vol. 47, Issue 3) Peer-Reviewed

  Mar. 201241 words Brief article 1880LPertuzumab (Genentech, a member of the Roche Group) in combination with Herceptin (trastuzumab) and docetaxel chemotherapy for people with HER2-positive metastatic or locally recurrent, unresectable breast cancer, who...

• Optimizing the Duration of Trastuzumab: A Fresh Perspective.

  Authors:Melissa A. Taylor, Kristina F. Byers, and Jane L. MeiselFrom:Oncology (Vol. 34, Issue 8) Peer-Reviewed

  Aug. 20203,431 words Article 1610LIntroduction Prior to the introduction of trastuzumab, the first targeted anti-HER2 agent, in 1998, patients diagnosed with HER2-positive breast cancer felt like they were being handed a death sentence. Despite...

• Benzodiazepines/tianeptine/ trastuzumab: sudden death: case report

  From:Reactions Weekly (Issue 1306)

  June 19, 2010355 words Brief article, Case ... 1030L[S] A woman receiving trastuzumab developed left ventricular dysfunction and experienced sudden death, which may have been triggered by the use of tianeptine, diazepam and estazolam. In March 2008, at 57 years of...

• Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.

  Authors:Amir Ansaripour, Carin A. Uyl-de Groot, and W. Ken RedekopFrom:PharmacoEconomics (Vol. 36, Issue 1) Peer-Reviewed

  Jan. 20188,281 words Report Introduction Clinical guidelines have recommended a 1-year trastuzumab regimen as standard care for early human epidermal growth factor receptor 2 (HER2)-positive breast cancer; however, this recommendation can have a...

• For or against Adjuvant Trastuzumab for pT1a-bN0M0 Breast Cancer Patients with HER2-Positive Tumors: A Meta-Analysis of Published Literatures

  Authors:Qiong Zhou, Wenjin Yin, Yueyao Du, and Jinsong LuFrom:PLoS ONE (Vol. 9, Issue 1) Peer-Reviewed

  Jan. 2, 20143,994 words Article 1410LAuthor(s): Qiong Zhou 1, Wenjin Yin 1,*, Yueyao Du 1, Jinsong Lu 1,2,* Introduction The prognosis of patients with small, infracentimetric breast cancer that are regional lymph node (including ipsilateral...

• Reorienting the Fab Domains of Trastuzumab Results in Potent HER2 Activators

  Authors:Justin M. Scheer, Wendy Sandoval, J. Michael Elliott, Lily Shao, Elizabeth Luis, Sock-Cheng Lewin-Koh, et al.From:PLoS ONE (Vol. 7, Issue 12) Peer-Reviewed

  Dec. 20, 20129,841 words Article 1550LThe structure of the Fab region of antibodies is critical to their function. By introducing single cysteine substitutions into various positions of the heavy and light chains of the Fab region of trastuzumab, a potent...

• Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA

  Authors:Felipe Ades, Christelle Senterre, Dimitrios Zardavas, Evandro de Azambuja, Razvan Popescu, and Martine PiccartFrom:PLoS ONE (Vol. 12, Issue 3) Peer-Reviewed

  Mar. 14, 20175,581 words Report 1370LBackground The development of trastuzumab is considered to be one of the greatest improvements in breast cancer treatment in recent years. This study aims to evaluate changes in the uptake of trastuzumab over the...

• Vela Pharmaceuticals Inc. (Trials in progress: Phase 2)

  From:Applied Clinical Trials (Vol. 12, Issue 4) Peer-Reviewed

  Apr. 2003152 words Brief article Vela Pharmaceuticals Inc. (Lawrenceville, NJ) completed its Phase 2 study of very low dosage cyclobenzaprine. The study included 36 subjects suffering from fibromyalgia syndrome and poor sleep. Subjects took a 1-4 mg...

• Trastuzumab improves the survival chances of women with HER2 breast cancer

  From:Nursing Standard (Vol. 26, Issue 36) Peer-Reviewed

  May 9, 2012220 words Brief article 1410LAdding trastuzumab (Herceptin) to the treatment offered to women who have HER2-positive breast cancer increases the chance of life being prolonged significantly, a review of the evidence has found. About a fifth of...

• Trastuzumab: first report of migraine: case report

  From:Reactions Weekly (Issue 1287)

  Feb. 6, 2010304 words Brief article, Case ... [*] A 31-year-old woman experienced migraines during chemotherapy with trastuzumab for breast cancer. The woman had a family history of migraine amongst both first- and second-degree relatives, although she...

• Trastuzumab: cardiomyopathy: 10 case reports

  From:Reactions Weekly (Issue 1276)

  Oct. 31, 2009258 words Brief article, Case ... [S] Ten patients [sexes not stated] developed cardiomyopathy during treatment with trastuzumab for breast cancer; all patients were identified as part of a retrospective study. All patients (aged 27-56 years), who...

• Trastuzumab: in HER2 and hormone receptor co-positive metastatic breast cancer

  Authors:Jennifer S. Orman and Caroline M. PerryFrom:Drugs (Vol. 67, Issue 18) Peer-Reviewed

  Dec. 1, 20074,961 words Article 2450L* Trastuzumab is a humanised [IgG.sub.1] monoclonal antibody, which selectively binds to the human epidermal growth factor receptor 2 (HER2), inhibiting cell proliferation and survival in HER2-dependent tumours. * In...

• Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.

  Authors:Anna Burguin, Daniela Furrer, Geneviève Ouellette, Simon Jacob, Caroline Diorio, and Francine DurocherFrom:PLoS ONE (Vol. 15, Issue 6) Peer-Reviewed

  June 25, 20207,730 words Report 1320LThe breast cancer (BC) biomarker HER2 (Human Epidermal Receptor 2) is overexpressed in 25% of BC. Only patients with HER2-positive tumors receive HER2-targeting therapies, like trastuzumab (Herceptin). However, some...

• Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using .sup.89Zr-DFO-Trastuzumab

  Authors:Jason P. Holland, Eloisi Caldas-Lopes, Vadim Divilov, Valerie A. Longo, Tony Taldone, Danuta Zatorska, et al.From:PLoS ONE (Vol. 5, Issue 1) Peer-Reviewed

  Jan. 25, 20108,400 words Article 1790LBackground The positron-emitting radionuclide .sup.89 Zr (t.sub.1/2 = 3.17 days) was used to prepare .sup.89 Zr-radiolabeled trastuzumab for use as a radiotracer for characterizing HER2/neu-positive breast tumors. In...

• [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model

  Authors:Tomomi Nakayama Iwata, Kiyoshi Sugihara, Teiji Wada, and Toshinori AgatsumaFrom:PLoS ONE (Vol. 14, Issue 10) Peer-Reviewed

  Oct. 1, 20195,677 words Report 1510L[Fam-] trastuzumab deruxtecan (DS-8201a) is a HER2 (ERBB2)-targeting antibody-drug conjugate, composed of a HER2-targeting antibody and a topoisomerase I inhibitor, exatecan derivative, that has antitumor effects in...

• An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer

  Authors:Aiko Sueta, Yutaka Yamamoto, Mutsuko Yamamoto-Ibusuki, Mitsuhiro Hayashi, Takashi Takeshita, Satoko Yamamoto, et al.From:PLoS ONE (Vol. 9, Issue 12) Peer-Reviewed

  Dec. 26, 20146,136 words Article 1490LThe phosphoinositide-3-kinase (PI3K) pathway is commonly deregulated in breast cancer through several mechanisms, including PIK3CA mutation and loss of phosphatase and tensin homolog (PTEN) and inositol polyphosphate...

• Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial

  Authors:Tallal Younis and Chris SkedgelFrom:PharmacoEconomics (Vol. 29, Issue 5) Peer-Reviewed

  May 20112,340 words Report 1980LThe clinical efficacy and 'value for money' (i.e. cost effectiveness) associated with newer treatments are often examined in randomized clinical trials (RCTs) and cost-effectiveness/cost-utility studies, respectively....

• Herceptin

  From:Formulary (Vol. 45, Issue 10) Peer-Reviewed

  Nov. 201038 words Brief article 1800LTrastuzumab (Herceptin, Genentech) was approved in combination with chemotherapy (cisplatin plus either capacitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic stomach or gastroesophageal junction cancer, in...